Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company's portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/28/18 | $250,000,000 | Series A |
6 Dimensions Capital Boyu Capital Hillhouse Capital Group Sirona Capital Temasek | undisclosed |
